A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice.
Collino. M M; Benetti. E E; Rogazzo. M M; Chiazza. F F; Mastrocola. R R; Nigro. D D; Cutrin. J C JC; Aragno. M M; Fantozzi. R R; Minetto. M A MA; Thiemermann. C C
Key Findings
- Ara‑290 treatment restored insulin signaling and glucose uptake in skeletal muscle.
- It reduced liver fat accumulation and normalized blood lipid and glucose levels.
- Kidney function improved and inflammatory myokines (IL‑6, FGF‑21) were lowered.
- Mitochondrial biogenesis in muscle was markedly increased.
Practical Outcomes
- For biohackers, ara‑290 looks like a promising candidate to counter diet‑induced insulin resistance and boost muscle mitochondria, but all data are from mice and the dosing (30 µg/kg subcutaneously for 11 weeks) may not translate to humans. More safety and human efficacy studies are needed before it can be incorporated into real‑world protocols.
Summary
In mice fed a high‑fat, high‑sugar diet, a synthetic peptide called ara‑290 (pHBSP) – a version of erythropoietin that doesn’t boost blood cells – improved several signs of metabolic disease. Over 11 weeks of daily injections, the mice showed better insulin sensitivity, lower blood sugar and fats, less liver fat, healthier kidneys, and more mitochondria (energy factories) in their muscles.
Abstract
The haematopoietic activity of erythropoietin (EPO) is mediated by the classic EPO receptor (EpoR) homodimer, whereas tissue-protective effects are mediated by a heterocomplex between EpoR and the β-common receptor (βcR). Here, we investigated the effects of a novel, selective ligand of this heterocomplex - pyroglutamate helix B surface peptide (pHBSP) - in mice fed a diet enriched in sugars and saturated fats. Male C57BL/6J mice were fed a high-fat high-sucrose diet (HFHS) for 22 weeks. pHBSP (30 μg·kg(-1) s.c.) was administered for the last 11 weeks. Biochemical assays, histopathological and immunohistochemical examinations and Western blotting were performed on serum and target organs (liver, kidney and skeletal muscle). Mice fed with HFHS diet exhibited insulin resistance, hyperlipidaemia, hepatic lipid accumulation and kidney dysfunction. In gastrocnemius muscle, HFHS impaired the insulin signalling pathway and reduced membrane translocation of glucose transporter type 4 and glycogen content. Treatment with pHBSP ameliorated renal function, reduced hepatic lipid deposition, and normalized serum glucose and lipid profiles. These effects were associated with an improvement in insulin sensitivity and glucose uptake in skeletal muscle. Diet-induced overproduction of the myokines IL-6 and fibroblast growth factor-21 were attenuated by pHBSP and, most importantly, pHBSP markedly enhanced mitochondrial biogenesis in skeletal muscle. Chronic treatment of mice with an EPO derivative, devoid of haematopoietic effects, improved metabolic abnormalities induced by a high-fat high-sucrose diet, by affecting several levels of the insulin signalling and inflammatory cascades within skeletal muscle, while enhancing mitochondrial biogenesis.
Study Information
pubmed
2014
2014-11-24T00:00:00.000Z
10.1111/bph.12888
24
67